Literature DB >> 27927710

Adrenocortical carcinoma, an unusual cause of secondary hypertension.

Daniel Veron Esquivel1, Fernando Batiz1, Alfonso Farias Vega1, Perla A Carrillo Gonzalez2.   

Abstract

We present the case of a female patient aged 39 years who was admitted to our hospital due to hypertension, severe hypokalaemia and metabolic alkalosis; physical examination was remarkable for plethoric moon face, centripetal obesity and bilateral lower extremity oedema. She was admitted for intravenous potassium replacement and further assessment of hypertension and associated clinical findings. Laboratory testing showed increased levels of aldosterone, renin, cortisol, testosterone and androstenedione. An abdominal CT revealed a large mass in the right adrenal gland with hepatic involvement. The patient was started on antihypertensive medications and underwent laparoscopic surgery for mass and liver biopsy. The pathological diagnosis was adrenocortical carcinoma with liver metastasis. Hyperaldosteronism is a cause of secondary hypertension and its diagnosis is usually benign. Adrenocortical carcinoma is a rare condition and aldosterone secreting tumours are even rarer; associated hypertension usually improves after tumour resection, but with the presence of metastasis, blood pressure control is difficult. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27927710      PMCID: PMC5174847          DOI: 10.1136/bcr-2016-217918

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Adrenocortical carcinoma: diagnosis, evaluation and treatment.

Authors:  Linda Ng; John M Libertino
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

2.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

Review 3.  Primary aldosteronism: diagnostic and treatment strategies.

Authors:  Cecilia Mattsson; William F Young
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

Review 4.  Renovascular hypertension and ischemic nephropathy.

Authors:  Stephen C Textor; Lilach Lerman
Journal:  Am J Hypertens       Date:  2010-09-23       Impact factor: 2.689

5.  Adrenocortical carcinoma. Clinical outcome at the end of the 20th century.

Authors:  R Vassilopoulou-Sellin; P N Schultz
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

6.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

7.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

8.  Ketoconazole in Cushing's disease: is it worth a try?

Authors:  Frederic Castinetti; Laurence Guignat; Pauline Giraud; Marie Muller; Peter Kamenicky; Delphine Drui; Philippe Caron; Fiorina Luca; Bruno Donadille; Marie Christine Vantyghem; Helene Bihan; Brigitte Delemer; Gerald Raverot; Emmanuelle Motte; Melanie Philippon; Isabelle Morange; Bernard Conte-Devolx; Laurent Quinquis; Monique Martinie; Delphine Vezzosi; Maelle Le Bras; Camille Baudry; Sophie Christin-Maitre; Bernard Goichot; Philippe Chanson; Jacques Young; Olivier Chabre; Antoine Tabarin; Jerome Bertherat; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2014-01-28       Impact factor: 5.958

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.

Authors:  John W Funder; Robert M Carey; Carlos Fardella; Celso E Gomez-Sanchez; Franco Mantero; Michael Stowasser; William F Young; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-06-13       Impact factor: 5.958

  10 in total
  1 in total

1.  Potassium losing, aldosterone producing adrenocortical carcinoma: a rare presentation.

Authors:  Zahir S Hussain; Smitha S Rao; Wajith Z Hussain; Shikhil Puzhakkal
Journal:  BMJ Case Rep       Date:  2020-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.